# Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

*PRI Rank #13 · Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026/rank-13*

| Field | Value |
| --- | --- |
| Rank | #13 |
| 18m citations | 156 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-024-03018-2 |
| Corresponding authors | Arun J. Sanyal |
| Institution | Virginia Commonwealth University, United States |

**Ranking page:** [Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026](https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026)

**Paper link:** [10.1038/s41591-024-03018-2](https://doi.org/10.1038/s41591-024-03018-2)

## Topics

retatrutide · triple hormone receptor agonist · glucose-dependent insulinotropic polypeptide receptor · GLP-1 receptor · glucagon receptor · Metabolic dysfunction-associated steatotic liver disease · Hepatic steatosis reduction · phase 2a trial · Subcutaneous administration · dose-response relationship · body weight reduction · abdominal fat · insulin sensitivity · Lipid metabolism · Hepatic steatosis reduction · MRI-PDFF

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```